Betaferon delays progress of MS

Betaferon (interferon beta-1b) has been shown to delay progression to clinically definite multiple sclerosis in patients with a single demyelinating event and MRI suggestive of multiple sclerosis.

In a controlled clinical trial, patients with a single demyelinating event treated with Betaferon had a 47% reduction in risk of developing multiple sclerosis compared with those receiving placebo. In a two-year period, clinically definite multiple sclerosis occurred in 45% of the placebo group compared with 28% of the Betaferon group.

Furthermore, Betaferon delayed the time to clinically definite multiple sclerosis by 363 days, from 255 days in the placebo group to 618 days in the Betaferon group.

Further information: Schering Health Care Ltd, The Brow, Burgess Hill, West Sussex RH15 9NE. Tel: 0845 609 6767.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases